Investigating alpha‐synuclein co‐pathology in Alzheimer's disease by means of cerebrospinal fluid alpha‐synuclein seed amplification assay
Alzheimer's & Dementia · 2024-04 · 20 (4) · 2444-2452
DOI: 10.1002/alz.13658 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 07.02.2024. Verfasst von Giovanni Bellomo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Memory Disturbances, Lab of Clinical Neurochemistry, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Peru…. Hauptthemen laut MEDLINE: Alzheimer Disease, Synucleinopathies, Lewy Body Disease, Parkinson Disease. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Parkinson's Foundation, Marie Skłodowska-Curie actions, Michael J Fox Foundation.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Lewy body disease, a frequently observed co‐pathology in Alzheimer's disease (AD), can be identified antemortem in cerebrospinal fluid (CSF) by α‐synuclein seed amplification assay (αS‐SAA). The prevalence and clinical impact of CSF αS‐SAA positivity in AD are still unknown. METHODS αS‐SAA was performed on CSF samples from 240 AD patients (preclinical, prodromal, and dementia stages), 85 controls, 84 patients with Parkinson's disease (PD), and 21 patients with PD with dementia or dementia with Lewy bodies. In AD patients, associations between αS‐SAA positivity and cognitive changes were also evaluated. RESULTS In agreement with available neuropathological studies, αS‐SAA positivity was observed in 30% of AD patients (vs 9% in controls), and was associated with cognitive decline, visuospatial impairment, and behavioral disturbances. DISCUSSION αS‐SAA positivity in AD patients reflects the prevalence observed in neuropathological series and is associated with a worse clinical outcome. These data confirm the validity of CSF αS‐SAA positivity as biomarker of synucleinopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Memory Disturbances, Lab of Clinical Neurochemistry, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
- R&D Unit, Amprion Inc, San Diego, California, USA.
- Section of Physiology and Biochemistry, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
ORCID-Profile: Giovanni Bellomo, Andrea Toja, Federico Paolini Paoletti, Carly M Farris, Lorenzo Gaetani, Davide Chiasserini, Anna Lidia Wojdaƚa, Luis Concha-Marambio, Lucilla Parnetti
Förderung
- Parkinson's Foundation
- Marie Skłodowska-Curie actions
- Michael J Fox Foundation
- European Union-Next Generation EU
Zitieren
APA
Bellomo, G., Toja, A., Paolini Paoletti, F., Ma, Y., Farris, C. M., Gaetani, L., Salvadori, N., Chiasserini, D., Wojdaƚa, A. L., Concha-Marambio, L., & Parnetti, L. (2024). Investigating alpha‐synuclein co‐pathology in Alzheimer's disease by means of cerebrospinal fluid alpha‐synuclein seed amplification assay. Alzheimer's & Dementia, 20(4), 2444-2452. https://doi.org/10.1002/alz.13658
Vancouver
Bellomo G, Toja A, Paolini Paoletti F, Ma Y, Farris CM, Gaetani L, et al. Investigating alpha‐synuclein co‐pathology in Alzheimer's disease by means of cerebrospinal fluid alpha‐synuclein seed amplification assay. Alzheimer's & Dementia. 2024;20(4):2444-2452. doi:10.1002/alz.13658
BibTeX
@article{Bellomo2024,
author = {Bellomo, Giovanni and Toja, Andrea and Paolini Paoletti, Federico and Ma, Yihua and Farris, Carly M and Gaetani, Lorenzo and Salvadori, Nicola and Chiasserini, Davide and Wojdaƚa, Anna Lidia and Concha-Marambio, Luis and Parnetti, Lucilla},
title = {Investigating alpha‐synuclein co‐pathology in Alzheimer's disease by means of cerebrospinal fluid alpha‐synuclein seed amplification assay},
journal = {Alzheimer's & Dementia},
year = {2024},
volume = {20},
number = {4},
pages = {2444--2452},
doi = {10.1002/alz.13658}
}
EUVIMED